Detalhe da pesquisa
1.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879077
2.
Moving toward disease modification in polycythemia vera.
Blood
; 142(22): 1859-1870, 2023 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729609
3.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591430
4.
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.
Br J Haematol
; 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38853641
5.
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.
J Natl Compr Canc Netw
; 22(2D)2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38862005
6.
Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia.
Acta Haematol
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38574468
7.
The role of therapy in the outcome of patients with myelofibrosis.
Cancer
; 129(18): 2828-2835, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243913
8.
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Cancer
; 129(7): 1017-1029, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36715486
9.
Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
Mod Pathol
; 36(3): 100016, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36788093
10.
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Am J Hematol
; 98(10): 1619-1626, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37485584
11.
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
Acta Haematol
; 146(6): 522-529, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37699357
12.
A review of essential thrombocythemia and its complications.
Clin Adv Hematol Oncol
; 21(2): 76-84, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780473
13.
Improved survival of patients with myelofibrosis in the last decade: Single-center experience.
Cancer
; 128(8): 1658-1665, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35077575
14.
Mechanistic basis and efficacy of targeting the ß-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Blood
; 135(15): 1255-1269, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068780
15.
Prediction of survival with intensive chemotherapy in acute myeloid leukemia.
Am J Hematol
; 97(7): 865-876, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35384048
16.
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.
Am J Hematol
; 97(1): 68-78, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716921
17.
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Am J Hematol
; 97(8): 1035-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583199
18.
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
Clin Infect Dis
; 72(10): 1755-1763, 2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32236406
19.
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
Cancer
; 127(17): 3113-3124, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914911
20.
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Cancer
; 127(3): 381-390, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33119202